AstraZeneca after £5m investment to develop UK R&D site
Global drugmaker, AstraZeneca, has successfully applied for a £5 million investment from the UK Department for Business, Innovation and Skills’ Regional Growth Fund. The investment will allow AstraZeneca to further explore the potential of developing a BioScience cluster on its Alderley Park R&,d site.
The venture will create a unique hub for pharmaceutical innovation and biotech enterprise in the North West, representing a positive example of progress for the UK’s life sciences sector.
“This initiative reflects the changing face of pharmaceutical R&,D and our focus on collaboration to access and develop the best science and technology. Alderley Park is a site of critical importance to our global R&,D organisation. By combining our capabilities with those of our partners and other enterprises, we aim to create a hub of scientific innovation with the potential to discover the medicines that people will need in years to come.”
Martin Mackay, President of R&,D at AstraZeneca.
AZ will now work, over the next three to six months, on the due diligence required to finalise the proposed plans.
Companies boosted by Regional Growth Fund awards (Manchester Business Awards)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.